Skip to Content

759 Results Found

  • Article
  • Open Access
7 Citations
5,139 Views
20 Pages

Altered DNA Methylation Profiles in SF3B1 Mutated CLL Patients

  • Alicja Pacholewska,
  • Christina Grimm,
  • Carmen D. Herling,
  • Matthias Lienhard and ,
  • Anja Königs,
  • Bernd Timmermann,
  • Janine Altmüller,
  • Oliver Mücke,
  • Hans Christian Reinhardt and
  • Michal R. Schweiger
  • + 8 authors+ 3 authors

28 August 2021

Mutations in splicing factor genes have a severe impact on the survival of cancer patients. Splicing factor 3b subunit 1 (SF3B1) is one of the most frequently mutated genes in chronic lymphocytic leukemia (CLL); patients carrying these mutations have...

(This article belongs to the Special Issue Genetics and Epigenetics in Complex Diseases)
  • Article
  • Open Access
11 Citations
3,818 Views
14 Pages

BTLA Expression in CLL: Epigenetic Regulation and Impact on CLL B Cell Proliferation and Ability to IL-4 Production

  • Lidia Karabon,
  • Anna Andrzejczak,
  • Lidia Ciszak,
  • Anna Tomkiewicz and ,
  • Aleksandra Szteblich,
  • Agnieszka Bojarska-Junak,
  • Jacek Roliński,
  • Dariusz Wołowiec,
  • Tomasz Wróbel and
  • Agata Kosmaczewska
  • + 5 authors+ 0 author

4 November 2021

In our previous study, while chronic lymphocytic leukemia (CLL) cases showed higher levels of B and T lymphocyte attenuator (BTLA) mRNA compared to controls, lower BTLA protein expression was observed in cases compared to controls. Hence we hypothesi...

(This article belongs to the Collection Trends and Advances in Tumor Immunology)
  • Article
  • Open Access
791 Views
19 Pages

Chronic Lymphocytic Leukemia (CLL)-Derived Extracellular Vesicles (EVs) Modulate Monocytes to Become CLL-Supportive Cells

  • Shaked Noah,
  • Einat Be’ery,
  • Zinab Sarsor,
  • Aladin Samara and ,
  • Pia Raanani and
  • Orit Uziel
  • + 1 author+ 0 author

In light of our previous publication, we hypothesized that chronic lymphocytic leukemia (CLL) cells also recruit monocytes to acquire survival advantage. To test this, we treated Buffy coat-driven monocytes with exosomes isolated from the peripheral...

(This article belongs to the Special Issue Current Insights into the Role of Exosomes in Intercellular Communication, 2nd Edition)
  • Article
  • Open Access
7 Citations
2,638 Views
19 Pages

Chronic Lymphocytic Leukemia (CLL)-Derived Extracellular Vesicles Educate Endothelial Cells to Become IL-6-Producing, CLL-Supportive Cells

  • Orit Uziel,
  • Lian Lipshtein,
  • Zinab Sarsor,
  • Einat Beery and ,
  • Shaked Bogen,
  • Meir Lahav,
  • Alon Regev,
  • Vitali Kliminski,
  • Roded Sharan and
  • Uri Rozovski
  • + 9 authors+ 4 authors

We hypothesized that via extracellular vesicles (EVs), chronic lymphocytic leukemia (CLL) cells turn endothelial cells into CLL-supportive cells. To test this, we treated vein-derived (HUVECs) and artery-derived (HAOECs) endothelial cells with EVs is...

(This article belongs to the Special Issue Exosomes and Their Role in Diseases)
  • Review
  • Open Access
33 Citations
7,426 Views
22 Pages

3 March 2023

Over the past decade, the treatment landscape of CLL has vastly changed from the conventional FC (fludarabine and cyclophosphamide) and FCR (FC with rituximab) chemotherapies to targeted therapies, including inhibitors of Bruton tyrosine kinase (BTK)...

(This article belongs to the Special Issue Targeted Drugs in Chronic Lymphocytic Leukemia)
  • Review
  • Open Access
11 Citations
5,372 Views
27 Pages

Proteomics and Drug Repurposing in CLL towards Precision Medicine

  • Dimitra Mavridou,
  • Konstantina Psatha and
  • Michalis Aivaliotis

6 July 2021

CLL is a hematological malignancy considered as the most frequent lymphoproliferative disease in the western world. It is characterized by high molecular heterogeneity and despite the available therapeutic options, there are many patient subgroups sh...

(This article belongs to the Special Issue Novel Drug Targets and Advances in Treatment of CLL)
  • Article
  • Open Access
1 Citations
2,732 Views
11 Pages

Genetic Lesions in Russian CLL Patients with the Most Common Stereotyped Antigen Receptors

  • Bella V. Biderman,
  • Ekaterina B. Likold,
  • Nataliya A. Severina,
  • Tatiana N. Obukhova and
  • Andrey B. Sudarikov

20 February 2023

Chronic lymphocytic leukemia (CLL) is one of the most common B-cell malignancies in Western countries. IGHV mutational status is the most important prognostic factor for this disease. CLL is characterized by an extreme narrowing of the IGHV genes rep...

(This article belongs to the Special Issue Genetics of Blood Disorders)
  • Review
  • Open Access
11 Citations
6,158 Views
9 Pages

The Role of Novel Agents in Treating CLL-Associated Autoimmune Hemolytic Anemia

  • Alessandro Noto,
  • Ramona Cassin,
  • Veronica Mattiello and
  • Gianluigi Reda

12 May 2021

Autoimmune cytopenias (AICs) have been reported as a common complication in chronic lymphocytic leukemia (CLL) with autoimmune hemolytic anemia (AIHA), accounting for most cases. According to iwCLL guidelines, AICs poorly responsive to corticosteroid...

(This article belongs to the Special Issue Diagnosis and Management of Autoimmune Hemolytic Anemias)
  • Review
  • Open Access
12 Citations
4,581 Views
14 Pages

The Mysterious Actor—γδ T Lymphocytes in Chronic Lymphocytic Leukaemia (CLL)

  • Michał K. Zarobkiewicz and
  • Agnieszka A. Bojarska-Junak

14 February 2022

Chronic lymphocytic leukaemia (CLL) is the most common leukaemia among adults. It is the clonal expansion of B cells expressing CD19 and CD5. Despite significant progress in treatment, CLL is still incurable. γδ T cells comprise an import...

(This article belongs to the Collection Trends and Advances in Tumor Immunology)
  • Feature Paper
  • Review
  • Open Access
103 Citations
11,718 Views
14 Pages

Venetoclax is a highly selective and effective B-cell lymphoma-2 (BCL-2) inhibitor, which is able to reinstate the apoptotic potential of cancer cells. With its full repertoire yet to be explored, it has changed the therapeutic landscape in haematolo...

(This article belongs to the Special Issue Targeted Treatment of Lymphoma, Leukaemia and Myeloma)
  • Review
  • Open Access
13 Citations
6,622 Views
16 Pages

Advancements in the Treatment of CLL: The Rise of Zanubrutinib as a Preferred Therapeutic Option

  • Stefano Molica,
  • Constantine Tam,
  • David Allsup and
  • Aaron Polliack

23 July 2023

Ibrutinib, the first-in-class Bruton’s tyrosine kinase inhibitor (BTKi), is a commonly deployed therapeutic option for previously untreated and relapsed/refractory (R/R) patients with chronic lymphocytic leukemia (CLL). The use of ibrutinib is,...

(This article belongs to the Special Issue Advanced Research in Oncology in 2023)
  • Article
  • Open Access
13 Citations
4,002 Views
15 Pages

IL-10 Rescues CLL Survival through Repolarization of Inflammatory Nurse-like Cells

  • Marcin Domagala,
  • Loïc Ysebaert,
  • Laetitia Ligat,
  • Frederic Lopez and ,
  • Jean-Jacques Fournié,
  • Camille Laurent and
  • Mary Poupot
  • + 2 authors+ 0 author

21 December 2021

Tumor-associated macrophages (TAMs) in chronic lymphocytic leukemia (CLL) are also called nurse-like cells (NLC), and confer survival signals through the release of soluble factors and cellular contacts. While in most patient samples the presence of...

(This article belongs to the Special Issue Targeting the Innate Immune Cells in Cancers)
  • Review
  • Open Access
19 Citations
8,329 Views
18 Pages

The Immunomodulatory Mechanisms of BTK Inhibition in CLL and Beyond

  • Qu Jiang,
  • Yayi Peng,
  • Carmen Diana Herling and
  • Marco Herling

23 October 2024

Bruton’s tyrosine kinase (BTK), a cytoplasmic tyrosine kinase, plays a pivotal role in B cell biology and function. As an essential component of the B cell receptor (BCR) signaling pathway, BTK is expressed not only in B cells but also in myelo...

(This article belongs to the Section Cancer Therapy)
  • Article
  • Open Access
2 Citations
4,107 Views
20 Pages

The Novel Anti-Cancer Agent, SpiD3, Is Cytotoxic in CLL Cells Resistant to Ibrutinib or Venetoclax

  • Alexandria P. Eiken,
  • Elizabeth Schmitz,
  • Erin M. Drengler,
  • Audrey L. Smith and ,
  • Sydney A. Skupa,
  • Kabhilan Mohan,
  • Sandeep Rana,
  • Sarbjit Singh,
  • Jayapal Reddy Mallareddy and
  • Dalia El-Gamal
  • + 7 authors+ 2 authors

27 August 2024

Background: B-cell receptor (BCR) signaling is a central driver in chronic lymphocytic leukemia (CLL), along with the activation of pro-survival pathways (e.g., NF-κB) and aberrant anti-apoptotic mechanisms (e.g., BCL2) culminating to CLL cell...

(This article belongs to the Section Leukemias)
  • Article
  • Open Access
9 Citations
6,171 Views
18 Pages

Targeting Nuclear NOTCH2 by Gliotoxin Recovers a Tumor-Suppressor NOTCH3 Activity in CLL

  • Rainer Hubmann,
  • Susanne Schnabl,
  • Mohammad Araghi,
  • Christian Schmidl and ,
  • André F. Rendeiro,
  • Martin Hilgarth,
  • Dita Demirtas,
  • Farghaly Ali,
  • Philipp B. Staber and
  • Medhat Shehata
  • + 8 authors+ 3 authors

18 June 2020

NOTCH signaling represents a promising therapeutic target in chronic lymphocytic leukemia (CLL). We compared the anti-neoplastic effects of the nuclear NOTCH2 inhibitor gliotoxin and the pan-NOTCH γ-secretase inhibitor RO4929097 in primary CLL...

(This article belongs to the Special Issue The Roles of Notch Signaling in Cancers)
  • Feature Paper
  • Review
  • Open Access
2 Citations
5,387 Views
11 Pages

Frontline Treatment of the Young, Fit Patient with CLL: A Canadian Perspective

  • Jacqueline Costello,
  • Matthew Kang and
  • Versha Banerji

30 September 2021

From a Canadian perspective, there has been a limited discussion on the frontline management of young, fit patients with chronic lymphocytic leukemia (CLL). The prevalence of this population ranges between 2 and 22 per 100,000 persons in Canada and v...

(This article belongs to the Section Hematology)
  • Article
  • Open Access
2 Citations
1,545 Views
18 Pages

The Combination of Ibrutinib with BH3 Mimetics or Dichloroacetate Is Effective in B-CLL

  • Joaquín Marco-Brualla,
  • Oscar Gonzalo,
  • Gemma Azaceta,
  • Isabel Izquierdo and ,
  • Luis Palomera,
  • Martín Villalba,
  • Isabel Marzo and
  • Alberto Anel
  • + 3 authors+ 0 author

29 August 2025

Since its discovery, the BTK inhibitor ibrutinib has redefined the standard treatments for hematological cancers, such as chronic lymphocytic leukemia (CLL). However, concerns exist regarding its secondary effects in humans and its occasional lack of...

(This article belongs to the Section Cellular Metabolism)
  • Brief Report
  • Open Access
3 Citations
3,578 Views
8 Pages

Ex Vivo Mitochondrial Respiration Parallels Biochemical Response to Ibrutinib in CLL Cells

  • Subir Roy Chowdhury,
  • Cheryl Peltier,
  • Sen Hou,
  • Amandeep Singh and ,
  • James B. Johnston,
  • Spencer B. Gibson,
  • Aaron J. Marshall and
  • Versha Banerji
  • + 3 authors+ 0 author

19 January 2021

Mitochondrial respiration is becoming more commonly used as a preclinical tool and potential biomarker for chronic lymphocytic leukemia (CLL) and activated B-cell receptor (BCR) signaling. However, respiration parameters have not been evaluated with...

(This article belongs to the Special Issue Novel Drug Targets and Advances in Treatment of CLL)
  • Article
  • Open Access
7 Citations
3,961 Views
15 Pages

Understanding the Impact of COVID-19 on Chronic Lymphocytic Leukemia (CLL) Caregiving and Related Resource Needs

  • Diliara Bagautdinova,
  • Kelsey C. Bacharz,
  • Carma L. Bylund,
  • Maria Sae-Hau and ,
  • Elisa S. Weiss,
  • Michelle Rajotte,
  • Greg Lincoln,
  • Taylor S. Vasquez,
  • Naomi D. Parker and
  • Carla L. Fisher
  • + 6 authors+ 1 author

18 February 2023

Chronic lymphocytic leukemia (CLL) caregivers play a central role in disease management—a role that has been heightened during the COVID-19 pandemic given the healthcare system’s reliance on frontline family caregivers and CLL patients&rs...

(This article belongs to the Special Issue Challenges in the Management of Blood Diseases during COVID-19 Pandemic)
  • Review
  • Open Access
35 Citations
5,695 Views
14 Pages

Role of Chronic Lymphocytic Leukemia (CLL)-Derived Exosomes in Tumor Progression and Survival

  • Nancy Nisticò,
  • Domenico Maisano,
  • Enrico Iaccino,
  • Eleonora Vecchio and ,
  • Giuseppe Fiume,
  • Salvatore Rotundo,
  • Ileana Quinto and
  • Selena Mimmi
  • + 3 authors+ 0 author

14 September 2020

Chronic lymphocytic leukemia (CLL) is a B-lymphoproliferative disease, which consists of the abnormal proliferation of CD19/CD5/CD20/CD23 positive lymphocytes in blood and lymphoid organs, such as bone marrow, lymph nodes and spleen. The neoplastic t...

(This article belongs to the Special Issue Exosomes as a Tool for Disease Progression Monitoring in Humans and Animals)
  • Article
  • Open Access
9 Citations
5,162 Views
17 Pages

Optimized Xenograft Protocol for Chronic Lymphocytic Leukemia Results in High Engraftment Efficiency for All CLL Subgroups

  • Sarah Decker,
  • Anabel Zwick,
  • Shifa Khaja Saleem,
  • Sandra Kissel and ,
  • Andres Rettig,
  • Konrad Aumann and
  • Christine Dierks
  • + 2 authors+ 0 author

12 December 2019

Preclinical drug development for human chronic lymphocytic leukemia (CLL) requires robust xenograft models recapitulating the entire spectrum of the disease, including all prognostic subgroups. Current CLL xenograft models are hampered by inefficient...

(This article belongs to the Special Issue The Importance of Tumor-Host Interactions in Adult B-Cell Leukemias and Lymphomas)
  • Review
  • Open Access
4 Citations
2,395 Views
14 Pages

Resistance Mutations in CLL: Genetic Mechanisms Shaping the Future of Targeted Therapy

  • Samantha Sekeres,
  • Erica N. Lamkin,
  • Eduardo Bravo,
  • Allison Cool and
  • Justin Taylor

10 September 2025

Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in Western populations and remains incurable despite significant therapeutic advancements. Over the past decade, the treatment landscape has evolved from traditional chemoimmunoth...

(This article belongs to the Special Issue Progress in Hematology: Non-Malignant, Pre-Malignant, and Malignant Disorders, and Genetically Based Therapies)
  • Review
  • Open Access
306 Views
23 Pages

27 October 2026

Background: Evaluating multidimensional value in chronic lymphocytic leukemia (CLL) is complicated by distinct endpoint hierarchies, patient heterogeneity, therapeutic resistance mechanisms, and healthcare costs. Consequently, addressing these multif...

(This article belongs to the Special Issue Advances in Precision Medicine for Chronic Lymphocytic Leukemia)
  • Article
  • Open Access
2 Citations
2,429 Views
15 Pages

γδ T Are Significantly Impacted by CLL Burden but Only Mildly Influenced by M-MDSCs

  • Michał Zarobkiewicz,
  • Wioleta Kowalska,
  • Agata Szymańska,
  • Natalia Lehman and ,
  • Bożena Kowalczyk,
  • Waldemar Tomczak and
  • Agnieszka Bojarska-Junak
  • + 2 authors+ 0 author

14 January 2025

Background/Objectives. The current study explores the impact of CLL on γδ T cells and, in an attempt to better understand the sources of immunosuppression, assesses the impact of M-MDSCs on γδ T cells in vitro. Methods. The st...

(This article belongs to the Topic The Tumor Microenvironment, Immuno-Oncology, and Immune Checkpoint: Implications for Current and Emergent Immunotherapies, 2nd Edition)
  • Article
  • Open Access
5 Citations
3,495 Views
14 Pages

AID Contributes to Accelerated Disease Progression in the TCL1 Mouse Transplant Model for CLL

  • Maria Schubert,
  • Franz Josef Gassner,
  • Michael Huemer,
  • Jan Philip Höpner and ,
  • Ekaterina Akimova,
  • Markus Steiner,
  • Alexander Egle,
  • Richard Greil,
  • Nadja Zaborsky and
  • Roland Geisberger
  • + 5 authors+ 0 author

26 May 2021

Adaptive somatic mutations conferring treatment resistance and accelerated disease progression is still a major problem in cancer therapy. Additionally in CLL, patients receiving novel, efficient drugs frequently become treatment refractory and event...

(This article belongs to the Special Issue Systems Biology and Intra-tumor Heterogeneity)
  • Article
  • Open Access
4 Citations
3,098 Views
13 Pages

Immunoprofiling of 4-1BB Expression Predicts Outcome in Chronic Lymphocytic Leukemia (CLL)

  • Kübra Kaban,
  • Sarah M. Greiner,
  • Samuel Holzmayer,
  • Claudia Tandler and ,
  • Sophie Meyer,
  • Clemens Hinterleitner,
  • Helmut R. Salih,
  • Melanie Märklin and
  • Jonas S. Heitmann
  • + 4 authors+ 0 author

4 November 2021

Recent success of novel therapies has improved treatment of chronic lymphocytic leukemia (CLL) patients, but most of them still require several treatment regimes. To improve treatment choice, prognostic markers suitable for prediction of disease outc...

(This article belongs to the Topic Cancer Biology and Therapy)
  • Article
  • Open Access
3 Citations
1,840 Views
14 Pages

Early Ibrutinib Dose Modifications in CLL: A Post Hoc Analysis of the Real-World EVIdeNCE Study

  • Stefano Molica,
  • Potito Rosario Scalzulli,
  • Lydia Scarfò,
  • Carla Minoia and ,
  • Roberta Murru,
  • Paolo Sportoletti,
  • Francesco Albano,
  • Nicola Di Renzo,
  • Alessandro Sanna and
  • Francesca Romana Mauro
  • + 33 authors+ 28 authors

19 March 2026

Background/Objectives: Ibrutinib has significantly improved outcomes in chronic lymphocytic leukemia (CLL), but evidence from real-world settings on the impact of early dose modifications and consequent relative dose intensity (RDI) maintenance on su...

(This article belongs to the Section Clinical Research in Cancer)
  • Case Report
  • Open Access
1 Citations
3,109 Views
7 Pages

Challenges in Diagnosis and Clinical Management of COVID-19 in Patient with B-Cell Chronic Lymphocytic Leukemia (CLL): Report of One Case

  • Vincenzo Visco,
  • Maria Enrichetta Lippi,
  • Gerardo Salerno,
  • Maria Angela Vittoria A. C. Licata and ,
  • Chiara de Dominicis,
  • Giusy Antolino,
  • Giacinto La Verde,
  • Iolanda Santino,
  • Maurizio Simmaco and
  • Salvatore Sciacchitano
  • + 5 authors+ 0 author

We report here a case of a patient affected by B-cell chronic lymphocytic leukemia (CLL) that developed COVID-19 during the actual SARS-CoV-2 outbreak. The coexistence of CLL and COVID-19 raises many questions regarding the possible increased risk of...

  • Review
  • Open Access
18 Citations
5,130 Views
13 Pages

6 February 2023

Over the last 10 years, the traditional treatment paradigms for CLL have been upended as the use of traditional chemoimmunotherapy regimens has declined in favor of novel targeted therapies. Targeted therapies have become the new standard of care in...

(This article belongs to the Special Issue Targeted Drugs in Chronic Lymphocytic Leukemia)
  • Review
  • Open Access
3 Citations
588 Views
13 Pages

Surrogate endpoints are increasingly used in chronic lymphocytic leukemia (CLL) to accelerate treatment evaluation, but their validity is context-dependent. This review examines key endpoints—progression-free survival (PFS), time to next treatm...

(This article belongs to the Special Issue Treatment and Prognosis of Hematological Malignancies)
  • Article
  • Open Access
16 Citations
4,349 Views
20 Pages

Enhanced Expression of miR-181b in B Cells of CLL Improves the Anti-Tumor Cytotoxic T Cell Response

  • Mirco Di Marco,
  • Serena Veschi,
  • Paola Lanuti,
  • Alice Ramassone and ,
  • Stefania Pacillo,
  • Sara Pagotto,
  • Felice Pepe,
  • Jonahunnatha Nesson George-William,
  • Claudia Curcio and
  • Rosa Visone
  • + 18 authors+ 13 authors

12 January 2021

The clinical progression of B cell chronic lymphocytic leukemia (CLL) is associated with immune cell dysfunction and a strong decrease of miR-181b-5p (miR-181b), promoting the death of CLL cells. Here we investigated whether the reduction of miR-181b...

(This article belongs to the Special Issue Chronic Lymphocytic Leukaemia (CLL))
  • Article
  • Open Access
9 Citations
3,802 Views
20 Pages

Low Serum Cholesterol Level Is a Significant Prognostic Factor That Improves CLL-IPI in Chronic Lymphocytic Leukaemia

  • Rui Gao,
  • Kaixin Du,
  • Jinhua Liang,
  • Yi Xia and ,
  • Jiazhu Wu,
  • Yue Li,
  • Bihui Pan,
  • Li Wang,
  • Jianyong Li and
  • Wei Xu
  • + 5 authors+ 0 author

Hypocholesterolaemia is associated with elevated cancer risk and mortality, yet the relation between chronic lymphocytic leukaemia (CLL) and serum lipid profile remains unclear. Our study aims to evaluate the prognostic value of cholesterol levels in...

(This article belongs to the Special Issue Lipid as a Cancer Therapeutic Target 2.0)
  • Article
  • Open Access
1 Citations
1,173 Views
23 Pages

miR-155-5p Silencing Does Not Alter BTLA Molecule Expression in CLL T Cells: Implications for Targeted Immunotherapy

  • Agata Kosmaczewska,
  • Lidia Ciszak,
  • Anna Andrzejczak,
  • Anna Tomkiewicz and ,
  • Anna Partyka,
  • Zofia Rojek-Gajda,
  • Irena Frydecka,
  • Dariusz Wołowiec,
  • Tomasz Wróbel and
  • Lidia Karabon
  • + 7 authors+ 2 authors

24 October 2025

Given that we have demonstrated that miR-155-5p is increased in CLL PBMCs and that its reduction with inhibitory siRNA partially restores the immune checkpoint BTLA protein level in CLL B cells, risk stratification for using anti-miR-155-based immuno...

(This article belongs to the Special Issue Epigenetic Drivers of Cancer Metastasis: From Methylation to Non-Coding RNAs)
  • Article
  • Open Access
1 Citations
1,616 Views
14 Pages

The Anti-SLAMF7 Antibody, Elotuzumab, Induces Antibody-Dependent Cellular Cytotoxicity Against CLL Cell Lines

  • Dominik Kľoc,
  • Bianca Dubiková,
  • Simona Žiláková,
  • Ján Sykora and ,
  • Michaela Šuliková,
  • Slavomír Kurhajec,
  • Ján Sabo,
  • Tomáš Guman and
  • Marek Šarišský
  • + 4 authors+ 0 author

3 February 2026

SLAMF7, also known as CD319, a SLAM (signaling lymphocytic activation molecule) family receptor, is relatively weakly expressed on chronic lymphocytic leukemia (CLL) B cells. This study evaluated the ability of elotuzumab (E), an anti-SLAMF7/CD319 an...

  • Article
  • Open Access
8 Citations
2,997 Views
14 Pages

A Small Molecule Antagonist of CX3CR1 (KAND567) Inhibited the Tumor Growth-Promoting Effect of Monocytes in Chronic Lymphocytic Leukemia (CLL)

  • Wen Zhong,
  • Parviz Kokhaei,
  • Tom A. Mulder,
  • Amineh Ghaderi and ,
  • Ali Moshfegh,
  • Jeanette Lundin,
  • Marzia Palma,
  • Johan Schultz,
  • Thomas Olin and
  • Mohammad Hojjat-Farsangi
  • + 7 authors+ 2 authors

13 November 2024

Background/Objectives: Nurse-like cells (NLCs) derived from monocytes in the tumor microenvironment support the growth of chronic lymphocytic leukemia (CLL) cells. Here, we investigated the effects of a CX3CR1 (fractalkine receptor) antagonist (KAND5...

(This article belongs to the Section Cancer Immunology and Immunotherapy)
  • Article
  • Open Access
4 Citations
4,479 Views
42 Pages

Synthesis and Pro-Apoptotic Effects of Nitrovinylanthracenes and Related Compounds in Chronic Lymphocytic Leukaemia (CLL) and Burkitt’s Lymphoma (BL)

  • Andrew J. Byrne,
  • Sandra A. Bright,
  • James. P. McKeown,
  • Adam Bergin and ,
  • Brendan Twamley,
  • Anthony M. McElligott,
  • Sara Noorani,
  • Shubhangi Kandwal,
  • Darren Fayne and
  • Mary J. Meegan
  • + 7 authors+ 2 authors

14 December 2023

Chronic lymphocytic leukaemia (CLL) is a malignancy of the immune B lymphocyte cells and is the most common leukaemia diagnosed in developed countries. In this paper, we report the synthesis and antiproliferative effects of a series of (E)-9-(2-nitro...

(This article belongs to the Special Issue Design, Synthesis and Evaluation of Novel Anticancer Agents)
  • Case Report
  • Open Access
2 Citations
2,891 Views
12 Pages

A Peculiar CLL Case with Complex Chromosome 6 Rearrangements and Refinement of All Breakpoints at the Gene Level by Genomic Array: A Case Report

  • Michele Cennamo,
  • Davide Sirocchi,
  • Carolina Giudici,
  • Marzia Giagnacovo and ,
  • Guido Petracco,
  • Daniela Ferrario,
  • Simona Garganigo,
  • Angela Papa,
  • Emanuela Veniani and
  • Piergiorgio Modena
  • + 9 authors+ 4 authors

17 June 2023

Introduction: Chronic lymphocytic leukemia (CLL), the most common leukemia in Western countries, is a mature B-cell chronic lymphoproliferative disorder characterized by the accumulation of neoplastic CD5+ B lymphocytes, functionally incompetent and...

(This article belongs to the Section Hematology)
  • Article
  • Open Access
1 Citations
3,632 Views
67 Pages

Synthesis and Biochemical Evaluation of Ethanoanthracenes and Related Compounds: Antiproliferative and Pro-Apoptotic Effects in Chronic Lymphocytic Leukemia (CLL)

  • James P. McKeown,
  • Andrew J. Byrne,
  • Sandra A. Bright,
  • Clara E. Charleton and ,
  • Shubhangi Kandwal,
  • Ivan Čmelo,
  • Brendan Twamley,
  • Anthony M. McElligott,
  • Darren Fayne and
  • Mary J. Meegan
  • + 7 authors+ 2 authors

5 August 2024

Chronic lymphocytic leukemia (CLL) is a malignancy of mature B cells, and it is the most frequent form of leukemia diagnosed in Western countries. It is characterized by the proliferation and accumulation of neoplastic B lymphocytes in the blood, lym...

(This article belongs to the Special Issue Advances in Pharmaceutical Sciences: In Honor of Dr. Jean Jacques Vanden Eynde (JJ))
  • Article
  • Open Access
2 Citations
3,662 Views
12 Pages

Unmutated IGHV1-69 CLL Clone Displays a Distinct Gene Expression Profile by a Comparative qRT-PCR Assay

  • Selena Mimmi,
  • Domenico Maisano,
  • Vincenzo Dattilo,
  • Massimo Gentile and ,
  • Federico Chiurazzi,
  • Alessandro D’Ambrosio,
  • Annamaria Zimbo,
  • Nancy Nisticò,
  • Annamaria Aloisio and
  • Ileana Quinto
  • + 8 authors+ 3 authors

Chronic Lymphocytic Leukemia (CLL) is a heterogeneous disease characterized by variable clinical courses among different patients. This notion was supported by the possible coexistence of two or more independent CLL clones within the same patients, i...

(This article belongs to the Section Cancer Biology and Oncology)
  • Article
  • Open Access
7 Citations
4,313 Views
15 Pages

Association of Common Variants of TNFSF13 and TNFRSF13B Genes with CLL Risk and Clinical Picture, as Well as Expression of Their Products—APRIL and TACI Molecules

  • Monika Jasek,
  • Agnieszka Bojarska-Junak,
  • Maciej Sobczyński,
  • Marta Wagner and ,
  • Sylwia Chocholska,
  • Jacek Roliński,
  • Dariusz Wołowiec and
  • Lidia Karabon
  • + 3 authors+ 0 author

6 October 2020

Interactions between APRIL (TNFSF13) and its receptor TACI (TNFRSF13B) are implicated in providing survival benefits for chronic lymphocytic leukaemia (CLL) cells. Here we explored the relationship between TNFSF13 and TNFRSF13B SNPs and expression of...

(This article belongs to the Special Issue The Study of Cancer Susceptibility Genes)
  • Review
  • Open Access
34 Citations
10,095 Views
16 Pages

6 February 2025

Effective available treatment options for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who relapse after becoming refractory to both a covalent Bruton Tyrosine Kinase inhibitor (cBTKi) and a B cell leukemia/lymphoma...

(This article belongs to the Special Issue Updates in Chronic Lymphocytic Leukemia: 10 Years of Paradigm Change and Outlook for the Future)
  • Article
  • Open Access
1,376 Views
24 Pages

MicroRNA Deregulation and Immune Checkpoint Interactions in Common Variable Immunodeficiency and CLL-Associated Secondary Immunodeficiency

  • Paulina Mertowska,
  • Sebastian Mertowski,
  • Milena Czosnek,
  • Barbara Sosnowska-Pasiarska and ,
  • Aleksandra Krasińska-Płachta,
  • Zbigniew Krasiński,
  • Tomasz Urbanowicz,
  • Krzysztof Bojarski,
  • Mansur Rahnama-Hezavah and
  • Ewelina Grywalska
  • + 5 authors+ 0 author

10 October 2025

Background: Immunodeficiencies are a heterogeneous group of disorders classified etiologically as primary (congenital) or secondary (acquired). Primary immunodeficiencies (PIDs), such as common variable immunodeficiency (CVID), result from genetic mu...

(This article belongs to the Special Issue MicroRNAs: Regulators of Cellular Fate)
  • Article
  • Open Access
2 Citations
3,320 Views
29 Pages

BCL2 Protein Progressively Declines during Robust CLL Clonal Expansion: Potential Impact on Venetoclax Clinical Efficacy and Insights on Mechanism

  • Hyunjoo Lee,
  • Shabirul Haque,
  • Rashmi Gupta,
  • Jonathan E. Kolitz and ,
  • Steven L. Allen,
  • Kanti Rai,
  • Nicholas Chiorazzi and
  • Patricia K. A. Mongini
  • + 3 authors+ 0 author

28 March 2024

CLL B cells express elevated pro-survival BCL2, and its selective inhibitor, venetoclax, significantly reduces leukemic cell load, leading to clinical remission. Nonetheless, relapses occur. This study evaluates the hypothesis that progressively dimi...

  • Article
  • Open Access
2 Citations
1,894 Views
12 Pages

Venetoclax-Based Regimens in CLL: Immunoglobulin G Levels, Absolute Neutrophil Counts, and Infectious Complications

  • Wojciech Szlasa,
  • Monika Kisielewska,
  • Anna Sobczyńska-Konefał,
  • Emilia Jaskuła and ,
  • Monika Mordak-Domagała,
  • Jacek Kwiatkowski,
  • Katarzyna Tatara,
  • Agnieszka Kuś,
  • Mateusz Sawicki and
  • Jarosław Dybko
  • + 8 authors+ 3 authors

Background: Chronic lymphocytic leukemia (CLL) is a prevalent hematologic malignancy that predominantly affects elderly individuals, posing significant clinical challenges due to patient comorbidities and inherent resistance to conventional chemother...

(This article belongs to the Special Issue Innovative Approaches to Molecular Pathogenesis and Therapy of Lymphoid Malignancies)
  • Article
  • Open Access
13 Citations
3,169 Views
18 Pages

15 June 2024

Venetoclax and obinutuzumab are becoming frontline therapies for chronic lymphocytic leukemia (CLL) patients. Unfortunately, drug resistance still occurs, and the combination could be immunosuppressive. Lysosomes have previously been identified as a...

(This article belongs to the Section Autophagy)
  • Article
  • Open Access
5 Citations
5,376 Views
17 Pages

Overall Survival Associated with Real-World Treatment Sequences in Patients with CLL/SLL in the United States

  • Joanna M. Rhodes,
  • Naleen Raj Bhandari,
  • Manoj Khanal,
  • Dan He and ,
  • Sarang Abhyankar,
  • John M. Pagel,
  • Lisa M. Hess and
  • Alan Z. Skarbnik
  • + 3 authors+ 0 author

7 August 2025

Background/Objectives: This study compared overall survival (OS) associated with common real-world treatment sequences in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in the United States. Methods: Utilizing the nat...

(This article belongs to the Section Cancer Therapy)
  • Article
  • Open Access
1 Citations
828 Views
21 Pages

CaMKK2 Expression Correlates with High-Risk CLL Biology, and Pharmacologic Inhibition Is Associated with Reduced Leukemic Cell Survival and Nurse-like Cell Support In Vitro

  • Shekeab Jauhari,
  • Alicia D. Cooper-Volkheimer,
  • Vini Verma,
  • Dilber Gökçe Kaplan and ,
  • Fahmin Basher,
  • J. Brice Weinberg,
  • Nelson J. Chao and
  • Luigi Racioppi
  • + 3 authors+ 0 author

20 July 2026

Background/Objectives: Chronic lymphocytic leukemia (CLL) is characterized by clinical and biological heterogeneity shaped by intrinsic signaling programs and microenvironmental interactions. Established biomarkers, including IGHV mutation status and...

(This article belongs to the Special Issue Immune Cell Signaling Networks in Tumor and Regenerative Stem Cell Niches)
  • Article
  • Open Access
120 Views
10 Pages

Associations of Chronic Lymphocytic Leukemia (CLL) Susceptibility Variants Across the CLL Etiologic Continuum

  • Raphael Mwangi,
  • Geffen Kleinstern,
  • Dennis Robinson,
  • Aaron D. Norman and ,
  • Kari G. Rabe,
  • Janet E. Olson,
  • Yuan Yao,
  • Nicholas J. Boddicker,
  • Rosalie Griffin and
  • Susan L. Slager
  • + 11 authors+ 6 authors

5 November 2026

Background: Low-count monoclonal B-cell lymphocytosis (LC-MBL) is a precursor to chronic lymphocytic leukemia (CLL). Forty-one inherited susceptibility variants for CLL have been reported, but whether these variants impact CLL, through the initiation...

(This article belongs to the Section Cancer Causes, Screening and Diagnosis)
  • Article
  • Open Access
3 Citations
2,081 Views
17 Pages

2 March 2025

This paper introduces a new two-stage multi-parallel-channel LED driver using a CLL-C resonant converter as the first stage and a Time Division Multiple Control circuit as the second stage. The first stage of the proposed converter topology has been...

(This article belongs to the Section F3: Power Electronics)

of 16